Key result
Apixaban with limited aspirin preserves safety and efficacy across multimorbidity in AF with ACS/PCI.
Why the study?
Patients with AF after ACS and/or PCI with multiple comorbidities have increased risk for bleeding and ischemic events, necessitating evaluation of antithrombotic regimens in this population.
Does apixaban and limiting aspirin improve bleeding and ischemic events in patients with atrial fibrillation after an acute coronary syndrome and/or undergoing percutaneous coronary intervention?
Does apixaban and limiting aspirin improve bleeding and ischemic events in patients with atrial fibrillation after an acute coronary syndrome and/or undergoing percutaneous coronary intervention?
This post-hoc analysis evaluates antithrombotic regimens in patients with AF and ACS/PCI across varying degrees of multimorbidity.
Answers are grounded in this paper and cite their sources.
May support apixaban plus P2Y12 inhibitor in multimorbid AF/ACS/PCI patients; extends evidence but remains hypothesis-generating.
Background: Patients with atrial fibrillation (AF) after an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) with multiple comorbidities are at increased risk for bleeding and ischemic events. Objectives: This post-hoc analysis of AUGUSTUS describes the safety and efficacy of antithrombotic regimens in patients with multimorbidity. Methods: inhibitor. Patients were categorized as having no multimorbidity (0-2 comorbidities), moderate multimorbidity (3-4 comorbidities), or high multimorbidity (≥5 comorbidities). The associations between multimorbidity and clinical outcomes and interactions with antithrombotic regimens were tested. Conclusions: inhibitor in patients with AF and ACS/PCI, irrespective of the presence of multimorbidity.
No takes yet. Share an insight, caveat, or question.
Krychtiuk et al. (2024) studied Atrial fibrillation after acute coronary syndrome and/or percutaneous coronary intervention. Apixaban and limiting aspirin was evaluated on clinical outcomes (p=0.608). Apixaban and limiting aspirin demonstrated consistent safety and efficacy in patients with atrial fibrillation and ACS/PCI, irrespective of multimorbidity.
Synapse has enriched 10 related papers. Consider them for comparative context: